Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Loss of ZNRF3/RNF43 unleashes EGFR in cancer.

eLife·2026
Same author

RSPO2-Based Peptibodies Conjugated with Pyrrolobenzodiazepine Dimer or Camptothecin Analogs Demonstrate Potent Antitumor Activity by Targeting the Three Receptors LGR4/5/6 in Colorectal Cancer and Neuroblastoma.

Journal of medicinal chemistry·2026
Same author

Multiple Transcriptome Analyses Reveal the Selected lncRNA-mRNA and circRNA-mRNA Networks in HepG2 Cells Expressing Genotype 4 Swine Hepatitis E Virus ORF3.

Veterinary sciences·2025
Same author

Bioinformatics Analysis of the Key lncRNAs of the Viral Response Pathway in HepG2 Expressing Genotype IV Swine Hepatitis E Virus ORF3.

Microorganisms·2025
Same author

Anti-tumor activity of camptothecin analog conjugate of an RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancer.

British journal of cancer·2025
Same author

Anti-tumor activity of camptothecin analog conjugate of a RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancer.

bioRxiv : the preprint server for biology·2024

相关实验视频

Updated: Sep 9, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.6K

基于RSPO2的体与罗二或坎普托西因类型结合,通过向三种受体LGR4/5/6表现出强烈的抗瘤活性.

Yukimatsu Toh, Jianghua Tu, Ling Wu

    bioRxiv : the preprint server for biology
    |September 2, 2025
    PubMed
    概括
    此摘要是机器生成的。

    针对LGR4/5/6受体的新型体药物联合体 (PDCs) 显示出强大的抗癌活性. 这些基于RSPO2的PDC证明了对结直肠癌和神经母细胞瘤的有效性,提供了一个有前途的新治疗策略.

    更多相关视频

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
    07:36

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

    Published on: May 16, 2020

    5.4K
    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
    09:44

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

    Published on: January 29, 2019

    10.2K

    相关实验视频

    Last Updated: Sep 9, 2025

    Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
    09:06

    Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

    Published on: February 3, 2023

    1.6K
    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
    07:36

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

    Published on: May 16, 2020

    5.4K
    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
    09:44

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

    Published on: January 29, 2019

    10.2K

    科学领域:

    • 癌症学
    • 分子生物学
    • 药物开发

    背景情况:

    • 在结直肠癌和神经母细胞瘤中,富含白的重复G蛋白结合受体4,5和6 (LGR4/5/6) 的表达高.
    • 这些受体结合R-spondins (RSPO) 并增强Wnt/β-catenin信号传递,这是癌症中的关键途径.
    • 同时向LGR4/5/6可以克服耐药性并提高治疗效果.

    研究的目的:

    • 开发和评估针对LGR4/5/6受体的新型体-药物联合体 (PDC).
    • 在结直肠癌和神经母细胞瘤的临床前模型中评估基于RSPO2的PDC的有效性.

    主要方法:

    • 产生一种突变的RSPO2域体,对LGR4/5/6有很高的亲和力,但缺乏信号活动.
    • 将RSPO2体与细胞毒药物 (pyrrolobenzodiazepine二聚体或坎普托西因衍生物) 结合.
    • 在癌细胞系和模型中对PDCs的细胞毒性和抗瘤活性进行体外和体内评估.

    主要成果:

    • 在实验室中,基于RSPO2的PDC对LGR4/5/ 6表达的神经母细胞瘤和结直肠癌细胞系表现出强烈的特异性细胞毒性.
    • 这些PDC在体内表现出强大的抗瘤活性.
    • 开发的PDC有效地向表达LGR4/5/6的癌细胞传递细胞毒性有效载荷.

    结论:

    • 基于RSPO2的体药物合物是结直肠癌和高危神经母细胞瘤的有希望的治疗策略.
    • 将这些PDC向LGR4/5/6受体提供了一种潜在的方法来克服各种癌症的耐药性.
    • 基于RSPO2的PDC的进一步开发需要对临床应用进行研究.